Paloma Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-31,190
| Closed | -$1.3M | – | 1186 |
|
|
2024
Q2 | $1.3M | Buy |
+31,190
| New | +$1.4M | 0.04% | 446 |
|
|
2024
Q1 | – | Sell |
-43,912
| Closed | -$2.25M | – | 796 |
|
|
2023
Q4 | $2.25M | Sell |
43,912
-30,733
| -41% | -$1.61M | 0.08% | 253 |
|
|
2023
Q3 | $4.33M | Sell |
74,645
-5,470
| -7% | -$335K | 0.15% | 121 |
|
|
2023
Q2 | $5.12M | Buy |
+80,115
| New | +$5.37M | 0.18% | 98 |
|
|
2023
Q1 | – | Sell |
-33,175
| Closed | -$2.34M | – | 766 |
|
|
2022
Q4 | $2.39M | Buy |
33,175
+29,866
| +903% | +$2.25M | 0.11% | 178 |
|
|
2022
Q3 | $235K | Sell |
3,309
-37,739
| -92% | -$2.74M | 0.01% | 679 |
|
|
2022
Q2 | $3.16M | Buy |
+41,048
| New | +$3.13M | 0.11% | 174 |
|
|
2022
Q1 | – | Sell |
-206,708
| Closed | -$12.9M | – | 1795 |
|
|
2021
Q4 | $12.9M | Buy |
+206,708
| New | +$12.1M | 0.19% | 67 |
|
|
2021
Q2 | – | Sell |
-137,800
| Closed | -$8.7M | – | 1803 |
|
|
2021
Q1 | $8.7M | Buy |
137,800
+22,100
| +19% | +$1.38M | 0.18% | 88 |
|
|
2020
Q4 | $7.18M | Buy |
115,700
+33,732
| +41% | +$2.07M | 0.19% | 108 |
|
|
2020
Q3 | $4.94M | Sell |
81,968
-167,146
| -67% | -$10.1M | 0.13% | 144 |
|
|
2020
Q2 | $14.6M | Buy |
249,114
+246,435
| +9,199% | +$14.7M | 0.25% | 57 |
|
|
2020
Q1 | $150K | Sell |
2,679
-11,794
| -81% | -$721K | 0.01% | 970 |
|
|
2019
Q4 | $929K | Buy |
14,473
+9,346
| +182% | +$535K | 0.01% | 994 |
|
|
2019
Q3 | $259K | Buy |
+5,127
| New | +$241K | 0.01% | 1617 |
|
|
2019
Q2 | – | Sell |
-16,619
| Closed | -$774K | – | 1741 |
|
|
2019
Q1 | $793K | Buy |
+16,619
| New | +$828K | 0.02% | 845 |
|
|
2018
Q4 | – | Sell |
-25,481
| Closed | -$1.58M | – | 1299 |
|
|
2018
Q3 | $1.58M | Buy |
+25,481
| New | +$1.51M | 0.03% | 553 |
|
|
2018
Q2 | – | Sell |
-12,809
| Closed | -$692K | – | 1649 |
|
|
2018
Q1 | $810K | Sell |
12,809
-3,841
| -23% | -$247K | 0.01% | 1101 |
|
|
2017
Q4 | $1.02M | Sell |
16,650
-4,686
| -22% | -$293K | 0.01% | 1026 |
|
|
2017
Q3 | $1.36M | Sell |
21,336
-27,908
| -57% | -$1.63M | 0.02% | 986 |
|
|
2017
Q2 | $2.74M | Sell |
49,244
-28,400
| -37% | -$1.55M | 0.03% | 570 |
|
|
2017
Q1 | $4.22M | Buy |
77,644
+46,801
| +152% | +$2.57M | 0.05% | 380 |
|
|
2016
Q4 | $1.8M | Sell |
30,843
-38,081
| -55% | -$2.08M | 0.02% | 750 |
|
|
2016
Q3 | $3.72M | Buy |
68,924
+47,907
| +228% | +$3.08M | 0.05% | 289 |
|
|
2016
Q2 | $1.55M | Sell |
21,017
-28,439
| -58% | -$2.01M | 0.02% | 873 |
|
|
2016
Q1 | $3.16M | Buy |
49,456
+3,015
| +6% | +$190K | 0.05% | 307 |
|
|
2015
Q4 | $3.19M | Buy |
46,441
+42,455
| +1,065% | +$2.81M | 0.08% | 211 |
|
|
2015
Q3 | $236K | Sell |
3,986
-15,785
| -80% | -$1M | 0.01% | 1401 |
|
|
2015
Q2 | $1.32M | Sell |
19,771
-5,889
| -23% | -$388K | 0.03% | 622 |
|
|
2015
Q1 | $1.66M | Buy |
+25,660
| New | +$1.61M | 0.05% | 343 |
|
|
2014
Q4 | – | Sell |
-12,680
| Closed | -$649K | – | 1160 |
|
|
2014
Q3 | $649K | Sell |
12,680
-2,603
| -17% | -$130K | 0.03% | 450 |
|
|
2014
Q2 | $741K | Buy |
+15,283
| New | +$753K | 0.03% | 426 |
|
|
2014
Q1 | – | Sell |
-90,260
| Closed | -$4.8M | – | 700 |
|
|
2013
Q4 | $4.8M | Buy |
+90,260
| New | +$4.6M | 0.24% | 98 |
|
|
2013
Q3 | – | Sell |
-48,358
| Closed | -$2.16M | – | 928 |
|
|
2013
Q2 | $2.16M | Buy |
+48,358
| New | +$2.1M | 0.12% | 152 |
|
Other funds holding BMY
Paloma Partners's BMY Position: Q3 2024 in Review
Paloma Partners sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 31,190 shares — an estimated $1.3M sold.
Paloma Partners first reported a position in BMY in Q2 2013 and held it in 34 quarters. The position peaked at $14.6M in Q2 2020. 2,263 funds tracked by Wall St. Rank hold BMY as of Q3 2024.
- Paloma Partners reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
- Paloma Partners sold 31,190 Bristol-Myers Squibb shares in Q3 2024, an estimated $1.3M.
- Paloma Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 34 quarters.
- Paloma Partners's Bristol-Myers Squibb position peaked at $14.6M in Q2 2020.
- 2,263 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.
Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.